KayoThera
Seattle, US · Founded 2019 · 2 known investors
Find your way into KayoThera
447 people in our graph share verified history with the KayoThera team — schools, employers, funds. One of them is your warm intro.
Christal Ngunlockedknows Mark Esposito · together at Princeton University (overlapped)
.png)
×8knows the team · via Middlebury College
×3knows the team · via Princeton University
Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
Founders & leadership
KayoThera was founded in 2019 by Mark Esposito and Yibin Kang.
ME
Mark EspositoinCSO, Co-Founder and Board MemberMark Esposito is Chief Scientific Officer and co-founder of Kayo Therapeutics, a biotechnology company developing therapeutics targeting metabolic disease and oncology. He has worked as a consultant to the biotech and pharmaceutical industry.
YK
Yibin KangChair, Scientific Advisory Board and Co-Founder
KM
Kendall MohlerExecutive
TQ
Thong Q. LePresident and CEO, Board Member
IH
Ian HowesChief Financial Officer
MK
Merika KodayinCOO and Board Member
Investors · 2
Funding
SEC filings, press & company announcements$11.2M disclosed across 2 of 3 rounds · 2019–2023
- Undisclosed amountSeries AJul 2023Source ↗
▶$10.5MraisedJul 2023 · 14 investors · OtherRule 506(b)
▶$10.5MraisedJul 2023 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Thong LeExecutive Officer, Director
- Mark EspositoExecutive Officer, Director
- Kendall MohlerExecutive Officer, Director
- Ian HowesExecutive Officer
- Offering amount
- $10.9M
- Amount sold
- $10.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$750KraisedJun 2019 · 1 investors · OtherRule 506(b)
▶$750KraisedJun 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mark EspositoExecutive Officer, Director
- Yibin KangDirector
- George F. HeinrichDirector
- James M. GolubieskiDirector
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapCoya Therapeutics35 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
SonoThera19 shared keywordsSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
AltaThera Pharmaceuticals19 shared keywordsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
RayThera19 shared keywordsRayThera develops small molecule therapies targeting unmet needs in immunology. The company focuses on drug discovery in the biotechnology and immunology space.
Kite Pharma18 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies competing with KayoThera for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does KayoThera do?
- Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
- Who founded KayoThera?
- KayoThera was founded by Mark Esposito, Yibin Kang in 2019.
- Who are KayoThera's investors?
- KayoThera's investors include 7G BioVentures, Foundation Venture Capital Group, LLC.
- How much funding has KayoThera raised?
- KayoThera has disclosed $11.2M raised across 2 of its 3 known rounds.
- Where is KayoThera headquartered?
- KayoThera is headquartered in Seattle, US.